Reference number : 236-2017-2018-Q1-00155, amendment number : , agreement type : G, recipient legal name : Ellenbogen, Mark A, recipient country : CA, recipient province : QC, recipient city : Montreal, recipient postal code : H3G 1M8, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 696150.0, agreement start date : 2017-04-01, agreement end date : 2022-03-31, description english : Improving treatment efficacy: A randomized controlled trial of the combined used of intranasal oxytocin and cognitive behavioral therapy for the treatment of major depressive disorder, description french : Improving treatment efficacy: A randomized controlled trial of the combined used of intranasal oxytocin and cognitive behavioral therapy for the treatment of major depressive disorder, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2017-18 to 2021-22), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2017-18 à 2021-22), owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada